RVSN:NASDAQRail Vision Ltd. Analysis
Data as of 2026-04-29 - not real-time
$7.78
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Rail Vision Ltd. (RVSN) is trading at a steep discount to its book value, with a price‑to‑book ratio of 0.77 and an upside potential of over 670% based on its 52‑week high. The stock shows technical signs of a possible rebound: the 14‑day RSI sits at 27 (oversold), the MACD histogram has turned positive and the MACD signal is flagged as bullish, while price is holding just above the identified support of $7.31. Fundamentals are mixed – revenue surged by 132% year‑over‑year and cash on hand stands at $19.9 million, yet operating margins are negative (-4.8%) and both EBITDA and free cash flow remain deeply in the red. Volatility is extreme at 75% over the past month and beta is near 3, indicating the stock moves sharply with market swings. Recent press releases highlight expanding orders in Israel, Latin America and the United States and a strategic push into AI‑powered thermal imaging, suggesting a growth narrative that has yet to translate into profitability. The combination of a low market cap (~$17 million), thin trading volume and a beta‑adjusted risk profile makes the share highly speculative, even as the balance sheet is relatively clean with negligible debt. Investors should weigh the attractive valuation against the uncertain path to sustainable earnings, the high price volatility, and the company’s reliance on winning large contracts in a regulated rail safety market.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Oversold RSI and bullish MACD signal suggest a near‑term price bounce
- Proximity to support level limits downside risk
- High volatility and thin volume increase short‑term uncertainty
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Revenue growth exceeding 130% and expanding international footprint
- Strong cash position with minimal debt supports operational runway
- Strategic AI and thermal‑imaging product rollout could unlock new contracts
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Valuation discount to book provides margin of safety
- Persistent operating losses and negative cash flow raise profitability concerns
- Regulatory and sector dynamics could materially affect future earnings
Key Metrics & Analysis
Financial Health
Revenue Growth131.90%
P/E Ratio-3.7
ROE-58.37%
ROA-34.00%
Debt/Equity1.22
P/B Ratio0.8
Op. Cash Flow$-9122000
Free Cash Flow$-5886625
Industry P/E30.8
Technical Analysis
TrendNeutral
RSI27.2
Support$7.31
Resistance$9.05
MA 20$8.39
MA 50$8.14
MA 200$253.16
MACDBullish
VolumeStable
Fear & Greed Index89.59
Valuation
Target Price$60.00
Upside/Downside671.21%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.90
Volatility75.30%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.